Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sac-TMT + MK-3475A + CRT vs CRT in MIBC (TroFuse-055)
NCT07829783Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Primary completion
- Nov 2031
01
Overview
A Phase 3 trial of sacituzumab tirumotecan, berahyaluronidase alfa + pembrolizumab in muscle-invasive bladder cancer (MIBC), sponsored by Merck & Co.. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecanberahyaluronidase alfa + pembrolizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07829783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07829783.